Frontier BioSciences, Inc.

Frontier BioSciences, Inc. Overview

Frontier BioSciences, Inc., headquartered in Maryland, and with toxicology facilities in Chengdu and Kunming, China, conducts IND-supporting preclinical toxicology studies, with in-house supporting capabilities in analytical chemistry and pathology. With current programs funded by the U.S. government, we have approved assurances with NIH OLAW, and our facilities and SOPs have been audited and approved by the U.S. Department of Defense.

Led by an experienced technical staff, our AAALAC-accredited facilities are equipped with advanced technologies to provide our clients with the knowledge needed to make better drug development decisions and guide their lead compounds forward in the drug development process.

Our preclinical toxicology scientific team includes 12 Study Directors with expertise and experience in animal disease modeling, PK/TK/ADME, general toxicology, safety pharmacology, developmental and reproductive toxicology, and genetic toxicology, to ensure these studies are conducted following the highest scientific standards.

With contractual partnership with primate breeding facilities, we can ensure guaranteed primate supply and immediate initiation of studies. As a result, reporting timelines, especially on PK studies, and study costs can be dramatically reduced.

Frontier’s in-house laboratory support services in histology, histopathology, clinical pathology, and bioanalytical chemistry, ensure the timeliness and integrity of your study, and leads to cost-effective programs. Additionally, our broad scope of offerings minimizes the number of additional outsourcing necessary to complete a study, reducing the time and resources required for project management and the associated risks.